» Authors » Smita Salian-Mehta

Smita Salian-Mehta

Explore the profile of Smita Salian-Mehta including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 92
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Clarke D, Datta K, French K, Leach M, Olaharski D, Mohr S, et al.
Regul Toxicol Pharmacol . 2024 Oct; 154:105729. PMID: 39481797
Minipigs are valid nonrodent species infrequently utilized for pharmaceutical research and development (R&D) compared with dogs or nonhuman primates (NHPs). A 2022 IQ DruSafe survey revealed a modest increase in...
2.
Matsumoto M, Polli J, Swaminathan S, Datta K, Kampershroer C, Fortin M, et al.
Clin Pharmacol Ther . 2024 Jun; 116(3):546-562. PMID: 38847597
Administration of a new drug candidate in a first-in-human (FIH) clinical trial is a particularly challenging phase in drug development and is especially true for immunomodulators, which are a diverse...
3.
Salian-Mehta S, Smith J, Flandre T, Lambert A, Lane J, Stokes A, et al.
Int J Toxicol . 2024 Apr; 43(4):377-386. PMID: 38606470
The inclusion of recovery animals in nonclinical safety studies that support clinical trials is undertaken with a wide diversity of approaches even while operating under harmonized regulatory guidance. While empirical...
4.
Salian-Mehta S, Poling J, Birkebak J, Rensing S, Carosino C, Santos R, et al.
Int J Toxicol . 2022 Dec; 42(2):111-121. PMID: 36543758
The presence of health issues (diarrhea, poor body condition) in non-human primates can impact animal welfare, confound toxicity study data, and lead to animal exclusion from studies. A working group...
5.
Janardhan K, Sura R, Salian-Mehta S, Flandre T, Palazzi X, Zane D, et al.
Toxicol Pathol . 2022 Oct; 50(8):950-956. PMID: 36226581
Nonclinical toxicology studies that are required to support human clinical trials of new drug candidates are generally conducted in a rodent and a non-rodent species. These studies typically contain a...
6.
Xiong W, Matheson C, Xu M, Backos D, Mills T, Salian-Mehta S, et al.
Mol Cancer Ther . 2016 Jan; 15(3):412-20. PMID: 26721946
Pituitary tumors of the gonadotrope lineage are often large and invasive, resulting in hypopituitarism. No medical treatments are currently available. Using a combined genetic and genomic screen of individual human...
7.
Salian-Mehta S, Xu M, McKinsey T, Tobet S, Wierman M
J Biol Chem . 2015 Apr; 290(22):14045-56. PMID: 25873389
The impact of histone deacetylases (HDACs) in the control of gonadotropin releasing hormone (GnRH) neuronal development is unknown. We identified an increase in many HDACs in GT1-7 (differentiated) compared with...
8.
Salian-Mehta S, Xu M, Pierce A, Bliesner B, Tobet S, Wierman M
Mol Cell Endocrinol . 2014 Jul; 393(1-2):164-70. PMID: 24978606
Prior work has shown the importance of TAM (Tyro3, Axl, Mer) receptor tyrosine kinases in GnRH neuronal development and reproductive function. It is unclear if TAM receptor actions are dependent...
9.
Salian-Mehta S, Xu M, Wierman M
Mol Cell Endocrinol . 2013 May; 374(1-2):92-100. PMID: 23648337
The membrane tyrosine kinase receptors, AXL and MET, are implicated in GnRH neuron migration and/or survival. We hypothesized that the receptors with their ligands, GAS6 and HGF, respectively may cross-talk...
10.
Salian-Mehta S, Doshi T, Vanage G
J Appl Toxicol . 2013 Apr; 34(3):307-18. PMID: 23620208
In light of the adverse reports of Bisphenol A (BPA) on reproduction and considering the pivotal role played by the steroid receptors (SRs) and their coregulators in male reproduction, it...